BioWorld

Jan. 29, 2007

Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth

Despite topping revenue estimates for the fourth quarter, Amgen's Inc.'s stock slipped more than $3 on news of unsettling Phase III Aranesp data. (BioWorld Today) Read More

Xcellerex Series B Gets $20M For FlexFactory Drug System

Opening The Risk Debate Crucial For Biotech's Future

Bush Backs Biofuel Use Yet Again In Address To Nation

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026